Biostatistics and Research Methods for Ophthalmologists

Biostatistics and Research Methods for Ophthalmologists

Last updated: October 2026

The statistics, study design and research ethics that appear in every ophthalmology exam and every journal club, explained with eye examples. Includes a calculator for diagnostic test accuracy.

Diagnostic tests: the 2 × 2 table

Disease presentDisease absent
Test positiveTrue positive (TP)False positive (FP)
Test negativeFalse negative (FN)True negative (TN)
  • Sensitivity = TP ÷ (TP + FN): of those with disease, how many test positive. A sensitive test, if negative, rules disease out (SnNout).
  • Specificity = TN ÷ (TN + FP): of those without disease, how many test negative. A specific test, if positive, rules disease in (SpPin).
  • Positive predictive value = TP ÷ (TP + FP) and negative predictive value = TN ÷ (TN + FN). These depend on prevalence: screening for glaucoma in the general population (low prevalence) gives many false positives even with a good test.
  • Likelihood ratios: LR+ = sensitivity ÷ (1 − specificity); LR− = (1 − sensitivity) ÷ specificity. Unlike predictive values, they do not change with prevalence.

The default numbers show a test with 90% sensitivity and 90% specificity used where prevalence is 2%: the positive predictive value is only about 16%.

Measures of effect

MeasureFormulaExample (event in 20% of controls, 15% of treated)
Absolute risk reduction (ARR)Control risk − treated risk20% − 15% = 5%
Relative risk (RR)Treated risk ÷ control risk0.15 ÷ 0.20 = 0.75
Relative risk reduction (RRR)1 − RR25%
Number needed to treat (NNT)1 ÷ ARR1 ÷ 0.05 = 20
Odds ratio (OR)(a × d) ÷ (b × c) from a 2 × 2 tableUsed in case–control studies; close to RR when the outcome is rare
  • Confidence interval: the range of values compatible with the data. If a 95% CI for an RR or OR includes 1 (or for a difference includes 0), the result is not statistically significant at p < 0.05.
  • p-value: the probability of a result at least this extreme if there were truly no difference. It does not measure the size or importance of an effect.
  • Type I error (α): finding a difference that is not real (false positive). Type II error (β): missing a real difference. Power = 1 − β, usually set at 80–90%; it rises with sample size and effect size.

Study designs and the evidence pyramid

DesignWhat it doesEye exampleMain weakness
Systematic review and meta-analysisCombines all good trialsCochrane review of anti-VEGF for DMEOnly as good as the included trials; publication bias (funnel plot asymmetry)
Randomised controlled trialRandom allocation removes confoundingLiGHT (SLT vs drops), Protocol TCost, strict selection limits generalisability
Cohort studyFollows exposed and unexposed people forwardSmokers vs non-smokers for cataractConfounding, loss to follow-up
Case–control studyCompares cases with controls, looking back at exposuresUveal melanoma and sunlightRecall and selection bias
Cross-sectional studyMeasures prevalence at one time pointPrevalence of glaucoma in a districtCannot show cause and effect
Case series and case reportsDescribe new findingsFirst reports of a drug side effectNo comparison group

Common biases

  • Selection bias: the study population does not represent the target population (for example, tertiary hospital patients used to estimate community prevalence).
  • Lead-time bias: earlier diagnosis by screening makes survival look longer even if outcome is unchanged. Length-time bias: screening picks up slower, milder disease.
  • Recall bias (case–control studies), observer bias (reduced by masking), attrition bias (dropouts), and publication bias.
  • Confounding: a third factor linked to both exposure and outcome (for example, age in studies of diabetes and cataract). Randomisation, matching and multivariable analysis reduce it.

Trials: key terms

  • Intention-to-treat: analyse people in the groups they were randomised to, whatever happened; preserves randomisation. Per-protocol: only those who completed treatment as planned.
  • Masking (blinding): single (patient), double (patient and assessor). Non-inferiority trials test whether a new treatment is not worse than the standard by more than a set margin (for example faricimab vs aflibercept).
  • Survival analysis: Kaplan–Meier curves for time-to-event data such as graft survival or trabeculectomy failure, compared with the log-rank test; hazard ratios from Cox regression.

Agreement and reliability

  • Bland–Altman plot: agreement between two measurement methods (for example two tonometers): plots the difference against the mean, with the mean bias and 95% limits of agreement. Correlation is not agreement.
  • Kappa statistic: agreement between observers beyond chance for categories (for example grading of diabetic retinopathy): above 0.8 is very good, 0.6–0.8 good.
  • Intraclass correlation: reliability of continuous measurements.

Research ethics and consent

  • The Declaration of Helsinki sets the principles for research involving people; studies need ethics committee approval and informed consent. In India, research follows the ICMR National Ethical Guidelines and trials are registered with CTRI.
  • Consent for treatment: patients must be told about material risks, benefits and reasonable alternatives (UK: Montgomery 2015). Record the discussion, not just a signature.
  • Confidentiality can be broken only in limited situations, such as serious risk to others (for example an unsafe driver who refuses to stop).

Related: landmark trials, thesis topics, how to write a case report.

Key sources

  • Kirkwood BR, Sterne JAC. Essential Medical Statistics, 2nd ed. Blackwell; 2003
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10
  • Indian Council of Medical Research. National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017
  • World Medical Association. Declaration of Helsinki (2024 revision)

📘 Want more exam-ready material? See Most Commons in Ophthalmology on Kindle, or browse all my books.

Written by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi)

Consultant, Cataract & Refractive Surgery — among a small number of AIIMS-trained ophthalmologists practicing in Gujarat. Read full credentials & experience or view his 28 publications on ResearchGate.

📚 Also the author of OKAT Decoded and other high-yield ophthalmology exam-prep books used by residents and PG aspirants.

Looking for an eye specialist in Ahmedabad? Learn about our Eye Department or book a consultation with Dr. Dhaval Patel.